70 related articles for article (PubMed ID: 18354137)
1. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.
Pandit S; Wisniewski D; Santoro JC; Ha S; Ramakrishnan V; Cubbon RM; Cummings RT; Wright SD; Sparrow CP; Sitlani A; Fisher TS
J Lipid Res; 2008 Jun; 49(6):1333-43. PubMed ID: 18354137
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.
McNutt MC; Kwon HJ; Chen C; Chen JR; Horton JD; Lagace TA
J Biol Chem; 2009 Apr; 284(16):10561-70. PubMed ID: 19224862
[TBL] [Abstract][Full Text] [Related]
3. Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C.
Mikaeeli S; Ben Djoudi Ouadda A; Evagelidis A; Essalmani R; Ramos OHP; Fruchart-Gaillard C; Seidah NG
Cells; 2024 May; 13(10):. PubMed ID: 38786080
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9.
Melendez QM; Wooten CJ; Krishnaji ST; Knagge K; Kirchner D; Lopez D
Int J Biomed Investig; 2020; 3(1):. PubMed ID: 32587953
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibition protects mice from food allergy.
Lorant V; Klein M; Garçon D; Sotin T; Frey S; Cheminant MA; Ayer A; Croyal M; Flet L; Rimbert A; Colas L; Cariou B; Bouchaud G; Le May C
Transl Res; 2024 Mar; ():. PubMed ID: 38471633
[TBL] [Abstract][Full Text] [Related]
6. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
[TBL] [Abstract][Full Text] [Related]
10. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
11. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.
Sarkar SK; Matyas A; Asikhia I; Hu Z; Golder M; Beehler K; Kosenko T; Lagace TA
Front Physiol; 2022; 13():960272. PubMed ID: 36187800
[TBL] [Abstract][Full Text] [Related]
13. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology.
Sundararaman SS; Döring Y; van der Vorst EPC
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356856
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng F; Zhao J; Wang Y; Lu W; Liu Z; Zhou Y; Martin WR; Wang R; Huang J; Hao T; Yue H; Ma J; Hou Y; Castrillon JA; Fang J; Lathia JD; Keri RA; Lightstone FC; Antman EM; Rabadan R; Hill DE; Eng C; Vidal M; Loscalzo J
Nat Genet; 2021 Mar; 53(3):342-353. PubMed ID: 33558758
[TBL] [Abstract][Full Text] [Related]
15. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
Galvan AM; Chorba JS
J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
[TBL] [Abstract][Full Text] [Related]
16. Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations.
Wierød L; Cameron J; Strøm TB; Leren TP
Mol Genet Metab Rep; 2016 Dec; 9():86-93. PubMed ID: 27896130
[TBL] [Abstract][Full Text] [Related]
17. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
[TBL] [Abstract][Full Text] [Related]
18. Genetics of familial hypercholesterolemia.
Brautbar A; Leary E; Rasmussen K; Wilson DP; Steiner RD; Virani S
Curr Atheroscler Rep; 2015 Apr; 17(4):491. PubMed ID: 25712136
[TBL] [Abstract][Full Text] [Related]
19. The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.
De Castro-Orós I; Pocoví M; Civeira F
Appl Clin Genet; 2010; 3():53-64. PubMed ID: 23776352
[TBL] [Abstract][Full Text] [Related]
20. c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-α pathway to PCSK9-mediated LDLR degradation pathway.
Xu W; Liu L; Hornby D
Molecules; 2012 Oct; 17(10):12086-101. PubMed ID: 23085658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
